find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
298
Clinical Trials
Pediatric Oncology
Phase II
Accepting Patients
nct/study# NCT04322318 / COG-AREN1921
Treatment Of Actively Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) And Relapsed Favorable Histology Wilms Tumors (FHWT)
Learn More
Neuro-Oncology
Phase I/II
Active
nct/study# NA / CDA024-2021
Phase 1b/2, Open-Label Dose Escalation With Expansion Study Of A ACTIVE Investigational Product In Adult Subjects With Relapsed/Refractory Primary Or Secondary Central Nervous System Lymphoma, Followed By A Phase 2 Open-Label Single Dose Level Study Of The Study Drug In Adult Subjects With Relapsed/Refractory Primary Central Nervous System Lymphoma.
Learn More
Neuro-Oncology
Phase II
Active
nct/study# NCT04947319 / ONO-4059-09
An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)
Learn More
Neuro-Oncology
Phase II
Active
nct/study# NA / GDC-0084
A Phase 2 Study Of Paxalisib (GDC-0084) In Recurrent Or Refractory Primary Central Nervous System Lymphoma (PCNSL)
Learn More
Neuro-Oncology
Phase II
Active
nct/study# NA / 21-109
A Phase 2 study of Paxalisib (GDC-0084) in recurrent or refractory Primary Central Nervous System Lymphoma (PCNSL)
Learn More
Phase 1 Clinical Trials
Phase I/II
Accepting Patients
nct/study# NCT03994601 / CA043-001
A Phase 1/2 First-In-Human Study Of BMS-986288 Alone And In Combination With Nivolumab In Advanced Malignant Tumors
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.